Target intelligence / Profile preview

Integrin beta-2 (CD18)

Target
CD18
Molecular classification
Receptor
01

Overview

Integrin beta-2 (ITGB2), also known as CD18, is a critical cell-surface receptor subunit that is exclusively expressed on leukocytes. It non-covalently pairs with various alpha subunits (CD11a, CD11b, CD11c, and CD11d) to form functional heterodimeric beta-2 integrins, such as LFA-1 and Mac-1, which are essential for leukocyte adhesion, transmigration across the vascular endothelium, and immunological synapse formation. Genetically inherited mutations in the ITGB2 gene lead to leukocyte adhesion deficiency type I (LAD-I), a severe and often fatal immunodeficiency characterized by recurrent bacterial infections due to the inability of white blood cells to extravasate into tissues. In therapeutic development, CD18 has been targeted by monoclonal antibodies (such as erlizumab and rovelizumab) to inhibit excessive leukocyte infiltration in inflammatory conditions like hemorrhagic shock, stroke, and myocardial infarction, though these early trials faced efficacy and safety challenges. More recently, gene therapy (marnetegragene autotemcel) has been developed to restore functional ITGB2 expression in LAD-I patients, and novel conformation-specific CD18 inhibitors are being explored to target immunosuppressive myeloid cells in the tumor microenvironment.

Other names
ITGB2CD18Integrin subunit beta 2Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit betaComplement receptor C3 subunit betaMFI7LAD
02

Mechanism of action

Drugs targeting Integrin beta-2 (CD18) primarily act as antagonists or inhibitors to block the interaction between beta-2 integrin heterodimers (such as LFA-1 or Mac-1) and their ligands (like ICAM-1), thereby preventing leukocyte adhesion, extravasation, and inflammatory tissue damage. Alternatively, gene therapy (e.g., marnetegragene autotemcel) delivers a functional copy of the ITGB2 gene to restore CD18 expression and rescue leukocyte adhesion deficiency type I (LAD-I).

03

Biological functions

Immune responseSignal transductionOther
04

Disease associations

InfectionInflammationCancerOther
05

Safety considerations

Increased risk of infectionImpaired wound healingProgressive multifocal leukoencephalopathy (PML)Pulmonary toxicity (e.g., hemoptysis/coughing up blood observed in erlizumab trials)
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

CD18 expression levelLFA-1 expressionMac-1 expressionITGB2 mutation status

Beyond the preview

Go deeper on Integrin beta-2 (CD18).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Integrin beta-2 (CD18).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call